Wuhan Brightrun Pharmaceutical Technology Co., Ltd.
BRH
Company News
Tech Sharing
In the fields of diabetes and obesity treatment, GLP-1 receptor agonists have undoubtedly emerged as a shining star. Drugs such as semaglutide, liraglutide, exenatide, and tirzepatide are reshaping the lives of hundreds of millions of patients worldwide, thanks to their remarkable blood sugar-lowering and weight-loss effects.
2025-09-01
In the field of diabetes drug development and treatment monitoring, accurately measuring the blood concentrations of insulin and its analogs—such as human insulin, aspart insulin, glargine insulin, and degludec insulin—presents a central challenge. These compounds, characterized by their large molecular weights, significant endogenous interference, and extremely low exposure levels, place nearly exacting demands on analytical methods. Thanks to its deep-rooted technological expertise, Wuhan Brightrun Pharmaceutical Technology Co., Ltd. has successfully overcome these industry hurdles.
2025-07-23
At the event's outset, the company proudly honored its top-performing employees of the quarter by presenting them with certificates of recognition and bespoke awards, celebrating their unwavering dedication to excellence in the biopharmaceutical testing field. Whether it was the technical experts who meticulously manage experimental data or the skilled managers who seamlessly coordinate projects, each individual exemplified the company’s core value of "Professionalism Drives Value" through their relentless pursuit of precision and innovation. Their exemplary efforts have become the benchmark for the entire team to strive toward. The room erupted in enthusiastic applause—both a heartfelt acknowledgment of these role models and a powerful testament to Berriheng employees' collective determination to continuously elevate themselves to meet the highest standards.
2025-05-30
In February 2025, Wuhan Buruiheng Pharmaceutical Technology Co., Ltd. officially became a member unit of the Wuhan East Lake National Independent Innovation Demonstration Zone Biomedical Industry Association, marking the company's deep integration into the innovation ecosystem of Optics Valley Bio-City and launching a new journey of collaborative industry-academia-research development.
2025-05-29
In clinical diagnostics and medical research, precise measurement of estradiol and estrone levels is critically important. Estradiol plays a key role in female reproduction and male metabolism, while estrone is involved in endocrine regulation. Abnormal fluctuations in the levels of these two hormones have been linked to various diseases. However, detecting them poses significant challenges: as they are naturally occurring endogenous substances, conventional methods cannot be used to create reliable standard curves. Additionally, the commonly employed surrogate matrix approach is often cumbersome and complex to implement. Moreover, steroids in biological matrices exist in both bound and unbound forms, and without proper reference standards, enzymatic hydrolysis-based quantitative analysis requires carefully optimized conditions. On top of this, current detection methods struggle to achieve the ultra-low quantification limits required—often down to the picogram level—while also demanding relatively large sample volumes, which can limit the analysis of precious or limited samples. Fortunately, our company has just announced exciting progress in the field of bioanalysis, offering promising solutions that could overcome these longstanding challenges.
2025-05-15
Recently, Wuhan Buruiheng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as Wuhan Buruiheng) successfully completed the on-site audit of its laboratory facilities and operational system conducted by an expert team from the Wuhan Municipal Health Commission, smoothly obtaining Level 2 Biosafety (BSL-2, also known as P2) laboratory registration under.Record number: E Health Safety BSL-2 [2023] 01-14-021
2023-10-08